Skip to main content
SleepCited

Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review.

Armando L Morera-Fumero, Lourdes Fernandez-Lopez, Pedro Abreu-Gonzalez
Systematic Review Drug and alcohol dependence 2020 20 citations

Study Design

Study Type
Systematic Review
Population
Insomnia patients
Intervention
Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review.
Primary Outcome
efficacy of MLT and MLT agonists (melatoninergics) in improving the rate of B...
Effect Direction
Mixed
Risk of Bias
Unclear

Abstract

BACKGROUND: Hypnotics (HYP) and benzodiazepines (BZD) are medicines prescribed for the insomnia treatment. Many patients present difficulties in discontinuing the treatment once established. Melatonin (MLT) has been prescribed as a treatment for BZD/HYP detoxification. AIMS: The primary objective of this systematic review is to assess the efficacy of MLT and MLT agonists (melatoninergics) in improving the rate of BZD and/or HYP discontinuation among adults with primary insomnia attempting to discontinue BZD and/or HYP. The secondary objective is to evaluate the partial efficacy of melatoninergic drugs in the discontinuation of BZD and/or HYP consumption in subjects that could not stop their consumption. METHOD: A search on Web of Science and Scopus was carried out from database inception to July 1st, 2019. RESULTS: Three hundred and forty-nine articles were identified but only four were included in the final review. Two were cohort prospective, one placebo-control double blind and one double blind placebo-control cross-over designed study. Total withdrawal (TW) ranged from 0% to 25% in the placebo arm and from 64.3% to 77.8% in the MLT arm. In cohort studies TW figures ranged from 30.8% to 65%. Partial withdrawal ranged between 20% and 30.8% of patients that did not achieve TW with reduction figures of diazepam equivalent dose ranging from 25% to 75%. CONCLUSION: MLT has a place in the physician armamentarium to treat the suspension/reduction of BZD/HYP consumption in patients with primary insomnia.

TL;DR

MLT has a place in the physician armamentarium to treat the suspension/reduction of BZD/HYP consumption in patients with primary insomnia.

Used In Evidence Reviews

Similar Papers

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.